Abstract
AbstractBackgroundThis study examined 5-year overall, recurrence and distant metastasis-free survival (OS, RFS, MFS) of high- and intermediate-risk breast cancer (BC) patients who declined guideline-recommended adjuvant chemotherapy (CHT).MethodsIn the prospective multicenter cohort study BRENDA II, patients with primary BC were sampled over a period of four years (2009–2012). A multi-professional team (tumorboard) discussed recommendation for adjuvant CHT according to the German guideline. Potential differences in 5 year survival were analyzed using Kaplan–Meier curves and Cox regression. The hazard ratios (HR) were adjusted for age, Charlson Comorbidity Score, American Society of Anesthesiologist (ASA) physical status classification, and endocrine therapy.ResultsA total of 759 patients were enrolled of which 688 could receive CHT according to the guidelines (n = 219 had a clear indication, inn = 304 it was possible). For 360 patients, the tumorboard advised to perform CHT, for 304 it advised against and in 24 cases, no decision was documented. Of those with a positive suggestion, 83% received CHT. Until 5 years after diagnosis, 57 patients were deceased, 41 had at least one distant metastasis and 29 a recurrence. There was no evidence for differences in OS and MFS in patients who declined CHT despite tumorboard recommendation (HR 3.5, 95% CI 0.8–15.1 for OS, HR 1.9, 95% 0.6–6.6 for MFS). Patients who received CHT had significantly better 5-year RFS compared to those who declined (HR 0.3, 95% CI 0.1–0.9,p = 0.03). There was no evidence for different survival in those who had no CHT because of comorbidity and those who declined actively, neither for OS, MFS nor RFS.ConclusionThe prospective BRENDA II study demonstrates benefit in RFS by guideline adherence in adjuvant breast cancer treatment, indicating prospectively the value of internationally validated guidelines in breast cancer care.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference30 articles.
1. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2003;8(6):541–52. https://doi.org/10.1634/theoncologist.8-6-541.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 2007;18(7):1133–44. https://doi.org/10.1093/annonc/mdm271.
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1,2018 AWMF Registernummer: 032-045OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
4. Schwentner L, Van Ewijk R, Kurzeder C, Hoffmann I, König J, Kreienberg R, et al. Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients. Eur J Cancer. 2013;49(3):553–63. https://doi.org/10.1016/j.ejca.2012.08.011.
5. Wollschlager D, Meng X, Wockel A, Janni W, Kreienberg R, Blettner M, et al. Comorbidity-dependent adherence to guidelines and survival in breast cancer-Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients. Breast J. 2018;24(2):120–7.